Patient Safe Tumour Imaging Contrast Agents

According to the NHS, 43 million imaging procedures were performed in 2018 in the UK. Out of all imaging procedures, 12.8 million (approx. 30%) procedures were reperformed using an additional imaging technique (modality) due to the lack of imaging contrast resolution. This lead to patient treatment delays, operational inefficiencies and economic consequences for the healthcare providers in the UK.

Platina Biomedical Technologies has developed a disruptive multimodal contrast agent technology. The technology is capable of improving MRI/CT imaging contrast resolution at the target disease site, therefore, holds tremendous potential for the proactive detection and precise characterization of multiple medical conditions including cancer, gastrointestinal disorders, renal abnormalities, liver disorders and diseases of the brain.

Platina Biomedical Technologies aims to apply its multimodal contrast agent technology to develop prototypes for NanoDrones(TM), the world's first nanoparticle tumour imaging contrast agent product.

NanoDrones will be capable of improving targeted intratumoural contrast resolution in both MRI and CT imaging without causing any adverse effects in cancer patients.

The project will develop prototypes for NanoDrones and preclinically evaluate prototypes for the detection and staging of lung and pancreatic, two of the deadliest forms of cancer with the lowest patient survival rates in the UK.

In the long run, NanoDrones hold an unparalleled potential to revolutionize global cancer healthcare by significantly improving the precision in the cancer detection process and accuracy in the cancer staging process, ultimately leading to significantly improved patient survival, mortality rates and quality of life.